Skip to content
Drybench

Drybench Patent.

PALIPERIDONE PALMITATE, NDA 207946

The patents and exclusivities FDA's Orange Book lists for NDA 207946 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.

FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.

Orange Book captured
14 October 2026
Paragraph IV list captured
17 October 2026
Last checked
30 October 2026
Data-branch commit
dadcab56563716abea6c5e31a5e1970080c778ef

Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.

Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.

Open in the appPALIPERIDONE PALMITATE in the molecule app

Listed protection

Listed dates run from 5 Apr 2036 to 24 Nov 2041, each by its own rule; no one date stands for this product.

Earliest listed date
5 Apr 2036US 10,143,693, use patentRule R1 · Products 001, 002, 003, 004 · patent.txt lines 7,676, 7,678, 7,680, 7,682
Latest listed date
24 Nov 2041US 11,666,697, use patentRule R1 · Products 005, 006 · patent.txt lines 7,686, 7,691
Latest substance patent
None listed
Latest listed patent
24 Nov 2041US 11,666,697, use patentRule R1 · Products 005, 006 · patent.txt lines 7,686, 7,691
Latest exclusivity
None listed

18 use-code patents, blocking the coded use only

Products

Each product number FDA lists under NDA 207946, as listed. The sections below name products by these numbers.

  • Product 001 · INVEGA TRINZA

    Dosage form; route
    SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
    Strength
    273MG/0.875ML (273MG/0.875ML)
    Approval date as listed
    18 May 2015
    Type as listed
    RX
    Applicant as listed
    JANSSEN PHARMACEUTICALS INC

  • Product 002 · INVEGA TRINZA

    Dosage form; route
    SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
    Strength
    410MG/1.315ML (311.79MG/ML)
    Approval date as listed
    18 May 2015
    Type as listed
    RX
    Applicant as listed
    JANSSEN PHARMACEUTICALS INC

  • Product 003 · INVEGA TRINZA

    Dosage form; route
    SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
    Strength
    546MG/1.75ML (312MG/ML)
    Approval date as listed
    18 May 2015
    Type as listed
    RX
    Applicant as listed
    JANSSEN PHARMACEUTICALS INC

  • Product 004 · INVEGA TRINZA

    Dosage form; route
    SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
    Strength
    819MG/2.625ML (312MG/ML)
    Approval date as listed
    18 May 2015
    Type as listed
    RX
    Applicant as listed
    JANSSEN PHARMACEUTICALS INC

  • Product 005 · INVEGA HAFYERA

    Dosage form; route
    SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
    Strength
    1.092GM/3.5ML (312MG/ML)
    Approval date as listed
    30 Aug 2021
    Type as listed
    RX
    Applicant as listed
    JANSSEN PHARMACEUTICALS INC

  • Product 006 · INVEGA HAFYERA

    Dosage form; route
    SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
    Strength
    1.560GM/5ML (312MG/ML)
    Approval date as listed
    30 Aug 2021
    Type as listed
    RX
    Applicant as listed
    JANSSEN PHARMACEUTICALS INC

Listed patents

Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.

7 entries from 18 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.

  • US 10,143,693, use patent

    patent.txt lines 7,676, 7,678, 7,680, 7,682
    Expiry as listed
    5 Apr 2036
    Rule
    R1
    Flags
    use code U-2457
    Product numbers
    001, 002, 003, 004

  • US 10,143,693, use patent

    patent.txt lines 7,677, 7,679, 7,681, 7,683
    Expiry as listed
    5 Apr 2036
    Rule
    R1
    Flags
    use code U-2458
    Product numbers
    001, 002, 003, 004

  • US 11,304,951, use patent

    patent.txt lines 7,684, 7,689
    Expiry as listed
    7 May 2041
    Rule
    R1
    Flags
    use code U-3349
    Product numbers
    005, 006

  • US 11,324,751, use patent

    patent.txt lines 7,685, 7,690
    Expiry as listed
    7 May 2041
    Rule
    R1
    Flags
    use code U-3359
    Product numbers
    005, 006

  • US 12,208,100, use patent

    patent.txt lines 7,687, 7,692
    Expiry as listed
    7 May 2041
    Rule
    R1
    Flags
    use code U-3359
    Product numbers
    005, 006

  • US 12,208,100, use patent

    patent.txt lines 7,688, 7,693
    Expiry as listed
    7 May 2041
    Rule
    R1
    Flags
    use code U-4110
    Product numbers
    005, 006

  • US 11,666,697, use patent

    patent.txt lines 7,686, 7,691
    Expiry as listed
    24 Nov 2041
    Rule
    R1
    Flags
    use code U-3626
    Product numbers
    005, 006

Listed exclusivities

Each exclusivity FDA lists for NDA 207946, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.

The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 207946.

Paragraph IV list rows giving NDA 207946

The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 207946, each cell as listed.

FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.

The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.

Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.

Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 207946

  • Paliperidone Palmitate · Extended-release Injectable Suspension · 273 mg/0.875 mL and 410 mg/1.315 mL

    RLD/NDA as listed: Invega Trinza 207946
    First PIV submission
    14 Jul 2021
    ANDAs
    1
    180-day status
    blank
    Decision posted
    blank
    First applicant approval
    blank
    First marketing
    blank
    Last qualifying patent expiry (as listed by FDA)
    5 Apr 2036

  • Paliperidone Palmitate · Extended-release Injectable Suspension · 546 mg/1.75 mL

    RLD/NDA as listed: Invega Trinza 207946
    First PIV submission
    24 Jun 2020
    ANDAs
    1
    180-day status
    blank
    Decision posted
    blank
    First applicant approval
    blank
    First marketing
    blank
    Last qualifying patent expiry (as listed by FDA)
    5 Apr 2036

  • Paliperidone Palmitate · Extended-release Injectable Suspension · 819 mg/2.625 mL

    RLD/NDA as listed: Invega Trinza 207946
    First PIV submission
    30 Apr 2021
    ANDAs
    1
    180-day status
    blank
    Decision posted
    blank
    First applicant approval
    blank
    First marketing
    blank
    Last qualifying patent expiry (as listed by FDA)
    5 Apr 2036

Notes from the trace

  • R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.

Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week